Find out how one large pharma company is utilizing LeapAnalysis to cut data integration time, improve data quality and drive results directly to end users
This talk will explore the steps taken, and review some of the outcomes gained, by a leading pharmaceutical company to accelerate their data integration efforts for translational medicine. Find out how they brought together clinical data of different types, across different sources, using fully virtualized semantic technology combined with advanced data science & machine learning.
Semantic technologies are playing an increasing role in enriching data in pharma research through the use of better metadata. This approach makes data more FAIR (Findable, Accessible, Interoperable, & Reusable), thereby giving it higher value and usability. At the same time, machine learning provides a powerful mechanism for statistically parsing and manipulating data using automation. LeapAnalysis provides a single product that fuses both of these perspectives seamlessly together. Our core engine drives advanced data connectors that run on a combination of logic-based technologies for semantic search (FAIR Data principles) along with powerful statistics-based machine learning tech that automatically reads data schemas at the source and provides advanced analytics post search.
In this webinar, Dr. Eric Little, CEO of LeapAnalysis, and Dr. Tom Plasterer, Senior Director of Oncology Translational Medicine at AstraZeneca, will share their insights and experiences working together to implement virtualized semantics with machine learning for advanced analysis of complex data in translational medicine applications.
These industry experts will describe some of the traditional challenges facing researchers in the translational medicine space and how connecting data virtually from multiple sources (i.e., without copying data or building ETL pipelines) can be used to find real-world patterns that can accelerate research dramatically in the future.
Attend this webinar to learn how to:
Eric Little is Co-Founder & CEO of LeapAnalysis. He works on data science and scalable integration solutions for many large companies across several industries, currently focusing on life sciences. He received his Ph.D. in Philosophy and Cognitive Science in 2002 from the University at Buffalo, State University of New York. He has worked in both academia as a professor in several fields, as well as held multiple management positions in the software development industry. Dr. Little is a recognized expert in semantic technology, Big Data, analytics applications and formal ontology. Dr. Little has designed and helped to implement semantic technologies and analytics for use in various applied domains including: biomedicine, medical device manufacturing, medical fraud, waste and abuse detection, pharmaceuticals, medical management, threat prediction/mitigation, disaster management, national defense/intelligence, steel production and petrochemicals.
Dr. Plasterer has pursued interests in bioinformatics, clinical informatics, systems biology and biomarker discovery over the last 20 years in both industry and academia. He co-founded PanGenX (a personalized medicine/pharmacogenetics knowledge-based start-up), directed the project planning and data interpretation group at BG Medicine and held an adjunct professor position in the department of Chemistry and Chemical Biology at Northeastern University. He now leads translational science data strategy and FAIR data initiatives at AstraZeneca.